ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Drug developers at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

114 drug developers are at ESMO 2026 — 122 presentations on the program and 74 with a booth in the exhibit hall. Most represented: AstraZeneca (4 on the program), GSK (2 on the program), XYone Therapeutics (2 on the program). 77 of them have their own page in this guide. As of Nov 2, 2026.

All 1,879 organizations at ESMO 2026 →

Tumour type
Top represented
Showing 1–9 of 114 organizations
OrganizationESMO 2026 Attendance
AstraZeneca
Cambridge, United Kingdom
Large pharmaExhibitor
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan.
Booth
Exhibiting at Booth 8066
Poster
Fri Oct 23
13:00–15:00
Talk
Fri Oct 23
13:30
Pharmaceutical industry
YO Mentorship session · with Princess Margaret Cancer Centre
Poster
Fri Oct 23
15:15–16:00
Satellite
Fri Oct 23
18:15–19:45
AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care
Sponsored session · with Hanyang University
Lung & thoracic cancersBiomarkers & precision oncology
Satellite
Sat Oct 24
13:00–14:30
AstraZeneca - Advancing 1L Breast Cancer Care Across Subtypes: Recent Developments and Future Directions
Sponsored session · with Vall d'Hebron University Hospital
Breast cancer
Satellite
Sun Oct 25
10:15–11:45
AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer
Sponsored session · with Beaumont Hospital
Lung & thoracic cancersNursing & supportive care
Satellite
Sun Oct 25
12:00–13:00
Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care
Sponsored session · with Cyprus University of Technology
Breast cancerNursing & supportive care
Satellite
Mon Oct 26
13:00–14:30
AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer
Sponsored session · with Amsterdam UMC
Gastrointestinal cancers
Large pharmaExhibitor
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib.
Booth
Exhibiting at Booth 1023
Satellite
Fri Oct 23
18:15–19:45
GSK - From evidence to clinical practice: Long-term survival outcomes in advanced endometrial cancer
Sponsored session · with NYU Langone Perlmutter Cancer Center
Gynaecological cancers
Satellite
Sat Oct 24
13:00–14:30
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care
Sponsored session · with Hospital Universitario Puerta de Hierro Majadahonda
Gynaecological cancers
Talk
Mon Oct 26
11:05–11:30
Digital biology twins and predictive oncology in drug discovery and development
Digital health and AI in oncology: Transforming patient monitoring and care
XT
Biotech
Oncology drug developer studying antibody–drug conjugates for cancer treatment.
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
15:15–16:00
Poster
Mon Oct 26
12:00–12:45
BiotechExhibitor
South Korean biotech developing bacteriophage and endolysin-based medicines, including phage-derived candidates for colorectal cancer.
Booth
Exhibiting at Booth 1102
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Large pharmaExhibitor
Finnish pharmaceutical company that co-developed the prostate cancer drug darolutamide with Bayer.
Booth
Exhibiting at Booth 1047
Poster
Fri Oct 23
15:15–16:00
Biotech
Biotechnology company developing cell and viral therapies for cancer.
Poster
Sat Oct 24
12:00–12:45
M
mAbxience
Madrid, Spain
Biotech
Biotechnology company developing and manufacturing biosimilar medicines.
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
LEON study: A PK-driven biosimilarity study of MB11 to nivolumab in advanced melanoma
ePoster session 12
Melanoma & skin cancers
Large pharmaExhibitor
Healthcare company whose Innovative Medicine business markets oncology drugs including amivantamab, daratumumab and teclistamab.
Booth
Exhibiting at Booth 1029 · Johnson & Johnson Innovative Medicine
Satellite
Fri Oct 23
18:15–19:45
Satellite
Sat Oct 24
14:00–15:30
J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach
Sponsored session · with ZHAW Zurich University of Applied Sciences
Lung & thoracic cancersNursing & supportive care
Satellite
Sun Oct 25
13:00–14:30
Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC
Sponsored session · with Maastricht UMC+, European Institute of Oncology (IEO)
Lung & thoracic cancers
Large pharmaExhibitor
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies.
Booth
Exhibiting at Booth 8063 · Gilead and Kite Oncology
Poster
Fri Oct 23
13:00–15:00
Extending RWD–based external control arms from hematologic to lung malignancies for clinical and regulatory decision-making
ePoster session 25
Haematological malignanciesLung & thoracic cancers
Satellite
Sun Oct 25
18:30–20:00
Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions
Sponsored session · with Latin American Cooperative Oncology Group
Breast cancerGynaecological cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from drug developers

Tell us what you sell and we’ll find the people at these drug developers most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse ESMO 2026 by

Exhibit hall

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction